FIBCON: FIBrinogen CONcentrate in paediatric cardiopulmonary bypass

ISRCTN ISRCTN50553029
DOI https://doi.org/10.1186/ISRCTN50553029
EudraCT/CTIS number 2013-003532-68
Secondary identifying numbers 16254
Submission date
01/05/2014
Registration date
01/05/2014
Last edited
14/11/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Surgery
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Newborn babies and infants needing surgery for congenital heart disease suffer the most from bleeding within the chest. As a result, they are frequently exposed to many blood products, and may also suffer consequences of blood loss. We want to find out whether giving a new blood product, human fibrinogen concentrate, to these infants, will reduce bleeding and exposure to other blood products. A unique aspect of this study will be that study drug exposure and dose will be personalised to the patient on the basis of bleeding risk. Because bleeding risk cannot be estimated accurately before the operation, we will assess this during the operation using a test for coagulation, known as rotational thromboelastometry (ROTEM).

Who can participate?
Babies who are aged less than 36 weeks with congenital heart disease requiring surgery.

What does the study involve?
We will give the study drug to only those infants who are at higher risk of bleeding during the ROTEM screening during the operation. These infants will be randomly allocated to receive either fibrinogen or a placebo (dummy). Infants at lower risk will not be allocated to any group, but remain in the study, forming an observational group. All infants will receive standard care with respect to all other aspects.

What are the possible benefits and risks of participating?
As this is an early phase trial, it is impossible to delineate risks or benefits in any meaningful way.

Where is the study run from?
Evelina Children’s Hospital (UK)

When is the study starting and how long is it expected to run for?
The study starts in June 2014 and ends in March 2016

Who is funding the study?
CSL Behring (UK)

Who is the main contact?
Dr Shane Tibby
Shane.Tibby@gstt.nhs.uk

Contact information

Dr Shane Tibby
Scientific

2nd floor, Evelina Children’s Hospital
Westminster Bridge Road
London
SE1 7EH
United Kingdom

Email Shane.Tibby@gstt.nhs.uk

Study information

Study designRandomised; Interventional and Observational; Design type: Process of Care, Treatment, Cohort study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleFibrinogen concentrate supplementation in the management of bleeding during paediatric cardiopulmonary bypass: a phase 1B/2A, open-label dose-escalation study
Study objectivesFibrinogen concentrate supplementation during paediatric cardiopulmonary bypass may decrease the incidence and severity of postoperative bleeding, and reduce the need for transfusion of blood and ancillary blood products (platelets, fresh frozen plasma, and cryoprecipitate). The primary objective of this trial is to determine the dose of intraoperative fibrinogen concentrate required to achieve physiological levels of fibrin polymerization of 8 to 13 mm as measured by the rotational thromboelastometry (ROTEM) measure of fibrin-based clotting: FibTEM MCF (equating to plasma fibrinogen concentrations of 1.5 to 2.5 g/L), immediately prior to separation from cardiopulmonary bypass in neonates and children < 12 kg.
Ethics approval(s)London - London Bridge Research Ethics Committee, 26/02/2014, ref: 14/LO/0267
Health condition(s) or problem(s) studiedTopic: Children; Subtopic: All Diagnoses; Disease: All Diseases
InterventionFibrinogen concentrate: IMP will be administered while on cardiopulmonary bypass. Patients will be screened while on cardiopulmonary bypass (approx 1 hour before end of operation) using Rotational Thromboelastometry: FibTEM MCF. If MCF<7mm, patients will be randomised to IMP:placebo 2:1. Dose will be tailored to patient based upon measured FibTEM MCF and desired target range.; Study Entry : Registration and One or More Randomisations
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Fibrinogen concentrate
Primary outcome measure1. Fibrinogen concentration (measured using the Clauss method)
2. Fibrin polymerization (measured by rotational thromboelastometry Fib-TEM MCF) achieved within 5 minutes of completion of study drug
Secondary outcome measures1. Efficacy
1.1. Mediastinal drain losses in first 24 hours after PICU admission
1.2. Requirement for delayed sternal closure due to clinical bleeding/tamponade
1.3. Requirement for ancillary blood transfusions in first 24 hours post PICU admission
1.4. Use of intra- and post-operative ancillary clotting products
1.5. Fibrinogen levels and ROTEM variables at time points T4 – T6

2. Safety
1.1. Incidence of major thrombotic event/thromboembolic associated complications
1.2. Allergic/hypersensitivity reaction to study drug
Overall study start date01/06/2014
Completion date02/03/2016

Eligibility

Participant type(s)Patient
Age groupChild
SexBoth
Target number of participantsPlanned Sample Size: 90; UK Sample Size: 90
Total final enrolment111
Key inclusion criteria1. Congenital heart disease requiring non-emergency* surgery on cardiopulmonary bypass
2. Age range: >36 weeks corrected gestation
3. Weight 2.5 to 12 kg
4. Informed consent to participate
*Non-emergency is defined as surgery that can be delayed >24 hours following diagnosis of congenital heart disease
Key exclusion criteria1. Known pre-existing inherited coagulopathy
2. Known pre-existing inherited thrombophilia
3. Recent, acute (within previous 2 weeks) thrombosis in a major vessel or thrombotic related major complications (as defined in protocol sections 2.43 and 7.3)
4. Administration of antiplatelet agents (e.g. aspirin) <48 hours prior to surgery
5. Known hypersensitivity/allergy to the study drug or similar products
6. History of anaphylaxis
7. Enrolment in another clinical trial in the previous 3 months
8. Parent/guardian unable to provide informed consent (this can include insufficient understanding of the trial, as judged by the clinician taking consent)
9. Major comorbidity likely to increase risk of mortality from surgical procedure
10. Significant renal/liver impairment within 2 days of planned surgery (creatinine > 2x Upper Limit of Normal, Alanine Aminotransferase > 2x ULN)
Date of first enrolment01/06/2014
Date of final enrolment02/03/2016

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Evelina Children’s Hospital
London
SE1 7EH
United Kingdom

Sponsor information

Guy's and St Thomas' NHS Foundation Trust (UK)
Hospital/treatment centre

King’s Health Partners Clinical Trials Office
16th Floor, Tower Wing
Guy's Hospital
Great Maze Pond
London
SE1 9RT
England
United Kingdom

ROR logo "ROR" https://ror.org/00j161312

Funders

Funder type

Industry

CSL Behring
Private sector organisation / For-profit companies (industry)
Alternative name(s)
CSL Behring LLC, CSL Behring GmbH, CSL
Location
United States of America

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results 21/06/2019 No No
Results article results 01/12/2020 23/11/2020 Yes No
Other publications mechanistic sub-study of the FIBCON trial 09/11/2022 14/11/2022 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

14/11/2022: Publication reference added.
23/11/2020: Publication reference added.
21/06/2019: Added clinicaltrialsregister.eu link to basic results (scientific). Added total final enrollment.
15/05/2018: No publications found, verifying study status with principal investigator.